Commission européenne/Horizon 2020

5 nouveaux appels à projets de recherche et d’innovation en lien avec la crise sanitaire du COVID19

15 mai 2020
11 juin 2020

La Commission européenne vient de diffuser 5 nouveaux appels à projets de recherche et d’innovation (programme Horizon 2020) en lien avec la crise sanitaire du COVID19.

La dotation globale pour ces appels est de 122 millions d’euros et nous insistons plus particulièrement sur un des appel sur lequel les sciences humaines et sociales sont particulièrement attendues : 

Behavioural, social and economic impacts of the outbreak response SC1-PHE-CORONAVIRUS-2020-2C

Proposals should focus on lessons learnt: they should i) address how to mitigate social and economic impacts of the outbreak response related to health systems; ii) identify non-intended consequences of epidemic-control decisions; and iii) provide answers to social, including gendered, dynamics of the outbreak and the related public health response.

En savoir plus +Lire la suite

Repurposing of manufacturing for vital medical supplies and equipment

Proposals for innovation actions targeted under this topic should address the re-orientation and repurposing of production capacities to meet the urgent needs of our societies for vital medical supplies and equipment.

The scope covers:

  • The repurposing, adaptation and ramp-up of production lines to quickly adjust to new and urgent production needs, notably medical equipment (e.g. personal protective equipment (PPE), ventilators), diagnostic technologies already deployed based on advanced materials and/or biotechnologies, as well as service systems and automated systems of disinfection,
  • Demonstrate flexibility models for the supply chain for the repurposing of production lines and proper risk management in case of disruption of supply chains (or other necessary means for enabling production, such as energy feedstock),
  • Automation technologies that are less dependent on work force present in factories, certification/calibration/accreditation of production lines that have been repurposed or restarted after a shutdown,
  • Qualification of operators/technicians for new/repurposed production lines.

En savoir plus +Lire la suite

Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)

Innovation Actions of one of the following two categories to:

  1. Support solutions that are close-to-market (TRL 7) in one of the COVID-19 areas mentioned below and that have already received, or are about to receive, the CE marking to proceed to large scale testing, piloting and deployment operations in critical healthcare areas (or wherever else is relevant) (type 1); 
  2. Support market innovation (from lab-to-fab) for further developing and maturing innovative solutions that have already been validated in lab environments (TRL 6-7 or higher) with the aim to help accelerate developments and achieve conformity assessment (CE marking) (type 2). 

This topic addresses consortia consisting of innovative technology providers, including SMEs, and/or organisations that can offer the range of activities required to address the objectives of the topic; the latter could for example be based on Digital Innovation Hubs, digital health accelerators and knowledge hubs, Centres offering Pilot Lines or similar technology, business and/or knowledge transfer organisations. The innovative technology providers can be either members of the applicant consortia or selected through open calls organised by the consortium using financial support to third parties. The support offered could include access to product development, accelerator, incubator and technical services and capabilities such as testing and experimentation facilities together with expertise, prototyping, design, engineering or pilot manufacturing services as necessary, as well as providing support for medical certification and clinical validation. Any use of third party grants must result in minimal administrative burden for participants, and allow the fastest possible launch of the projects.

En savoir plus +Lire la suite

Pan-European COVID-19 cohorts

Specific Challenge

The COVID-19 pandemic created an urgent demand for evidence-based innovative and rapid solutions to deal with health and health-related emergencies, to offer the best possible care to patients, and to protect the general population and the frontline health care staff. This expression of interest is to complement research efforts in the fight against the coronavirus, in particular projects resulting from the first H2020 expression of interest, which is currently addressing epidemiology and modelling, diagnostics, treatment, and vaccine. In parallel, Research and Innovation should without delay start analysing the lessons from the present crisis, in particular its impact on health and socio-economic aspects, and propose recommendations for being better prepared in the future if confronted with similar events.

Proposals submitted under this expression of interest are expected to establish new and/or build on existing large-scale cohorts to rapidly advance the knowledge on the control of the SARS-CoV-2 infection, develop evidence-based recommendations for effective prevention of the spreading, protection of the population in the coming months/years, and optimized treatment of the COVID-19 patients. The population-based cohorts should also inform on longer-term consequences of COVID-19 on health and well-being of individuals.

The population-based COVID-19 cohort should include non-infected and infected individuals. The cohort should be large enough to provide valid and reliable evidence and robust recommendations, and be suitable for the conduct of retrospective and prospective studies. The cohort should include both sexes, all ages, all conditions (healthy, pregnant, physical or mental disabilities, chronic disorders, infectious diseases, etc.), all clinical outcomes (from no symptom to mortality), as well as a large spectrum of different clinical management practices and treatments. The inclusion of individuals who are SARS-CoV-2-negative should enable a prospective follow up and an analysis of vaccination response when vaccines will be available.

En savoir plus +Lire la suite

Networking of existing EU and international cohorts of relevance to COVID-19

Specific Challenge

Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens.


Proposals under this coordination and support action should support the international networking of existing, mainly longitudinal, cohorts in order to extract jointly agreed standardized data on COVID-19 diagnosed/serotyped and matched non-infected individuals. This effort should contribute to help in the identification of key factors influencing the susceptibility to infection and clinical manifestation, to assess the optimized therapeutic and clinical management options, and to derive lessons on the health and socio-economic impacts of the pandemic. They should develop cohort readiness to adapt rapidly to future crisis. Proposals should consider strategies to interact with the COVID-19 cohort(s) that will be funded under this expression of interest and international initiatives on cohorts, as well as liaising with the network of clinical trials on COVID-19.

En savoir plus +Lire la suite